## Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims**

- 1. (Original) An isolated protein comprising an amino acid sequence selected from the group consisting of:
  - (a) amino acid residues 1 to 234 of SEQ ID NO:2;
  - (b) amino acid residues 2 to 234 of SEQ ID NO:2;
  - (c) amino acid residues 1 to 234 of SEQ ID NO:4; and
  - (d) amino acid residues 2 to 234 of SEQ ID NO:4.
  - 2. (Original) The protein of claim 1, wherein the amino acid sequence is (a).
  - 3. (Original) The protein of claim 1, wherein the amino acid sequence is (b).
  - 4. (Original) The protein of claim 1, wherein the amino acid sequence is (c).
  - 5. (Original) The protein of claim 1, wherein the amino acid sequence is (d).
- 6. (Original) The protein of claim 1 wherein the amino acid sequence further comprises a heterologous polypeptide.
- 7. (Original) The protein of claim 6 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
  - 8. (Original) The protein of claim 1 wherein said protein is glycosylated.
- 9. (Original) The protein of claim 1 wherein said protein is fused to polyethylene glycol.
  - 10. (Original) An isolated protein produced by a method comprising:
    - (a) expressing the protein of claim 1 by a cell; and
    - (b) recovering the protein.
  - 11. (Original) A composition comprising the protein of claim 1 and a carrier.

- 12. (Previously Amended) An isolated protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of the full-length polypeptide encoded by the genomic DNA in ATCC Deposit No. 209005;
- (b) the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the genomic DNA in ATCC Deposit No. 209005;
- (c) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209006; and
- (d) the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209006.
  - 13. (Original) The protein of claim 12, wherein the amino acid sequence is (a).
  - 14. (Original) The protein of claim 12, wherein the amino acid sequence is (b).
  - 15. (Original) The protein of claim 12, wherein the amino acid sequence is (c).
  - 16. (Original) The protein of claim 12, wherein the amino acid sequence is (d).
- 17. (Original) The protein of claim 12 wherein the amino acid sequence further comprises a heterologous polypeptide.
- 18. (Original) The protein of claim 17 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
  - 19. (Original) The protein of claim 12 wherein said protein is glycosylated.
- 20. (Original) The protein of claim 12 wherein said protein is fused to polyethylene glycol.
  - 21. (Original) An isolated protein produced by a method comprising:
    - (a) expressing the protein of claim 12 by a cell; and
    - (b) recovering the protein.
  - 22. (Original) A composition comprising the protein of claim 12 and a carrier.
- 23. (Currently Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) at least 30 contiguous amino acid residues of SEQ ID NO:2;
- (b) at least 50 contiguous amino acid residues of SEQ ID NO:2;
- (c) at least 30 contiguous amino acid residues of SEQ ID NO:4; and
- (d) at least 50 contiguous amino acid residues of SEQ ID NO:4; wherein the isolated polypeptide regulates transcription in prostate tissue.
- 24. (Original) The polypeptide of claim 23, wherein the amino acid sequence is (a).
- 25. (Original) The polypeptide of claim 23, wherein the amino acid sequence is (b).
- 26. (Original) The polypeptide of claim 23, wherein the amino acid sequence is (c).
- 27. (Original) The polypeptide of claim 23, wherein the amino acid sequence is (d).
- 28. (Original) The polypeptide of claim 23 wherein the polypeptide is fused to a heterologous polypeptide.
- 29. (Original) The polypeptide of claim 28 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 30. (Original) The polypeptide of claim 23 wherein said polypeptide is glycosylated.
- 31. (Original) The polypeptide of claim 23 wherein said polypeptide is fused to polyethylene glycol.
  - 32. (Original) An isolated polypeptide produced by a method comprising:
    - (a) expressing the polypeptide of claim 23 by a cell; and
    - (b) recovering the polypeptide.
- 33. (Original) A composition comprising the polypeptide of claim 23 and a carrier.

- 34. (Currently Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) at least 30 contiguous amino acid residues encoded by the genomic in ATCC Deposit No. 209005;
- (b) at least 50 contiguous amino acid residues encoded by the genomic DNA in ATCC Deposit No. 209005;
- (c) at least 30 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209006; and
- (d) at least 50 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209006;

wherein the isolated polypeptide regulates transcription in prostate tissue.

- 35. (Original) The polypeptide of claim 34, wherein the amino acid sequence is (a).
- 36. (Original) The polypeptide of claim 34, wherein the amino acid sequence is (b).
- 37. (Original) The polypeptide of claim 34, wherein the amino acid sequence is (c).
- 38. (Original) The polypeptide of claim 34, wherein the amino acid sequence is (d).
- 39. (Original) The polypeptide of claim 34 wherein the polypeptide is fused to a heterologous polypeptide.
- 40. (Original) The polypeptide of claim 39 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 41. (Original) The polypeptide of claim 34 wherein said polypeptide is glycosylated.
- 42. (Original) The polypeptide of claim 34 wherein said polypeptide is fused to polyethylene glycol.
  - 43. (Original) An isolated polypeptide produced by a method comprising:

- (a) expressing the polypeptide of claim 34 by a cell; and
- (b) recovering the polypeptide.
- 44. (Original) A composition comprising the polypeptide of claim 34 and a carrier.
- 45. (Currently Amended) An isolated human protein consisting of an amino acid sequence at least 95% identical to

amino acid residues 1 to 234 of SEQ ID NO:2; wherein the isolated human protein regulates transcription in prostate tissue.

46-47. (Cancelled)

- 48. (Original) The protein of claim 45 wherein the amino acid sequence further comprises a heterologous polypeptide.
- 49. (Original) The protein of claim 48 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
  - 50. (Original) The protein of claim 45 wherein said protein is glycosylated.
- 51. (Original) The protein of claim 45 wherein said protein is fused to polyethylene glycol.
  - 52. (Original) An isolated protein produced by a method comprising:
    - (a) expressing the protein of claim 45 by a cell; and
    - (b) recovering the protein.
  - 53. (Original) A composition comprising the protein of claim 45 and a carrier.
- 54. (Currently Amended) An isolated human protein consisting of an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) the amino acid sequence of the full-length polypeptide encoded by the genomic DNA in ATCC Deposit No. 209005; and
- (b) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209006;

wherein the isolated human protein regulates transcription in prostate tissue.

55. (Original) The protein of claim 54, wherein the amino acid sequence is (a).

Application No.: 10/614,275 6 Docket No.: PF219D1

- 56. (Original) The protein of claim 54, wherein the amino acid sequence is (b).
- 57. (Original) The protein of claim 54 wherein the amino acid sequence further comprises a heterologous polypeptide.
- 58. (Original) The protein of claim 57 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
  - 59. (Original) The protein of claim 54 wherein said protein is glycosylated.
- 60. (Original) The protein of claim 54 wherein said protein is fused to polyethylene glycol.
  - 61. (Original) An isolated protein produced by a method comprising:
    - (a) expressing the protein of claim 54 by a cell; and
    - (b) recovering the protein.
  - 62. (Original) A composition comprising the protein of claim 54 and a carrier.
- 63. (Currently Amended) The polypeptide of claim 23 which comprises the amino acid sequence of amino acid resides 122-188 of SEQ ID NO:2.
- 64. (Currently Amended) The polypeptide of claim 23 which comprises the amino acid sequence of amino acid resides residues 124-183 of SEQ ID NO:2.